Forward Pharma A/S, a late-stage biotech developing treatments for multiple sclerosis and psoriasis, filed on Monday with the SEC to raise up to $200 million in an initial public offering.
The Copenhagen, Denmark-based company, which was founded in 2005, plans to list on the NASDAQ under the symbol FWP. Forward Pharma A/S initially filed confidentially on April 9, 2014. Leerink Partners is the sole bookrunner on the deal. No pricing terms were disclosed.
